Evaluation of the IMMULITE® 2000 CMV IgM assay

Area of Science:

• Clinical Diagnostics
• Immunology
• Virology

Background:

• Cytomegalovirus (CMV) infection diagnosis is difficult due to asymptomatic cases and non-specific symptoms.
• Laboratory testing is crucial for accurate CMV diagnosis.
• Detecting CMV IgM antibodies indicates primary CMV infection, vital for pregnant women and immunocompromised individuals.

Purpose of the Study:

• To evaluate the performance of the IMMULITE 2000 CMV IgM assay for diagnosing CMV infection.
• To assess the assay's reproducibility, normal range, and method comparison against a predicate assay.
• To determine the assay's utility in diverse patient populations, including pregnant and immunocompromised individuals.

Main Methods:

• Qualitative detection of CMV IgM antibodies in serum or plasma using the IMMULITE 2000 CMV IgM assay.
• Reproducibility testing across three sites.
• Method comparison study involving 718 patient samples, including CMV IgM-positive, pregnant, HIV-positive, immunosuppressed, transplant patients, and those with cross-reacting conditions.

Main Results:

• The IMMULITE 2000 CMV IgM assay showed excellent reproducibility (total CV < 10%).
• High overall agreement (>95%) was observed when compared to the VIDAS CMV IgM assay across various patient groups.
• Agreements were approximately 96% for cross-reactive samples, 96% for immunocompromised, and 97% for pregnant subjects.

Conclusions:

• The IMMULITE 2000 CMV IgM assay is a reliable tool for diagnosing acute or recent CMV infections.
• The assay demonstrates excellent reproducibility and minimal cross-reactivity.
• Its performance is comparable to the VIDAS CMV IgM assay, making it suitable for clinical use.